Appendix 4E and Preliminary Financial Report
29 August 2018 The Directors of the Board present their report on...
Read MoreCLINUVEL Investor Summary
21 August 2018 Increasing interest has been seen in the interaction between...
Read MoreAppendix 4C
30 July 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read MoreCLINUVEL Newsletter - July 2018
27 July 2018 On 25 June 2018 CLINUVEL announced its New Drug...
Read MoreChange in substantial holding
17 July 2018 Enclosed is a notice of a change of interest...
Read MoreChange in Director's Interest Notice
6 July 2018 Enclosed is a change in director’s interest notice. Download...
Read MoreChange in substantial holding
04 July 2018 Enclosed is a notice of a change in substantial...
Read MoreCLINUVEL COMPLETES SCENESSE® FDA FILING
25 June 2018 EXECUTIVE SUMMARY First NDA for SCENESSE® (afamelanotide 16mg) in...
Read MoreTrading Halt
22 June 2018 Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV)...
Read More